Free Trial
NASDAQ:XLO

Xilio Therapeutics (XLO) Stock Price, News & Analysis

Xilio Therapeutics logo
$0.69 0.00 (0.00%)
As of 07/3/2025 03:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Xilio Therapeutics Stock (NASDAQ:XLO)

Key Stats

Today's Range
$0.67
$0.70
50-Day Range
$0.66
$1.15
52-Week Range
$0.62
$1.70
Volume
151,718 shs
Average Volume
1.42 million shs
Market Capitalization
$35.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Buy

Company Overview

Xilio Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

XLO MarketRank™: 

Xilio Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 1237th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Xilio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Xilio Therapeutics has received no research coverage in the past 90 days.

  • Read more about Xilio Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Xilio Therapeutics are expected to grow in the coming year, from ($1.14) to ($0.40) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Xilio Therapeutics is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Xilio Therapeutics is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Xilio Therapeutics has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Xilio Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    16.07% of the float of Xilio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Xilio Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Xilio Therapeutics has recently increased by 231.02%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Xilio Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Xilio Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.07% of the float of Xilio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Xilio Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Xilio Therapeutics has recently increased by 231.02%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Xilio Therapeutics has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Xilio Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    4 people have searched for XLO on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Xilio Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Xilio Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $72,977.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 5.20% of the stock of Xilio Therapeutics is held by insiders.

  • Percentage Held by Institutions

    54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Xilio Therapeutics' insider trading history.
Receive XLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

XLO Stock News Headlines

Gold is soaring. Here’s how to get paid from it
Gold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.
See More Headlines

XLO Stock Analysis - Frequently Asked Questions

Xilio Therapeutics' stock was trading at $0.9550 at the start of the year. Since then, XLO stock has decreased by 27.4% and is now trading at $0.6930.

Xilio Therapeutics, Inc. (NASDAQ:XLO) released its earnings results on Tuesday, May, 13th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.10 by $0.28. The firm had revenue of $2.93 million for the quarter, compared to analyst estimates of $42 million. Xilio Therapeutics had a negative trailing twelve-month return on equity of 262.69% and a negative net margin of 585.54%.

Xilio Therapeutics (XLO) raised $125 million in an IPO on Friday, October 22nd 2021. The company issued 7,353,000 shares at $16.00-$18.00 per share.

Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Xilio Therapeutics investors own include PayPal (PYPL), Achilles Therapeutics (ACHL), JPMorgan Chase & Co. (JPM), AT&T (T), United Microelectronics (UMC), Adverum Biotechnologies (ADVM) and atai Life Sciences (ATAI).

Company Calendar

Last Earnings
5/13/2025
Today
7/04/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:XLO
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+477.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$58.24 million
Net Margins
-585.54%
Pretax Margin
-585.54%

Debt

Sales & Book Value

Annual Sales
$9.27 million
Price / Cash Flow
N/A
Book Value
$0.40 per share
Price / Book
1.73

Miscellaneous

Free Float
49,089,000
Market Cap
$35.88 million
Optionable
Not Optionable
Beta
-0.15
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:XLO) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners